Genitourinary Cancers

Pembrolizumab plus gemcitabine and concurrent hypofractionated radiotherapy to treat patients with MIBC demonstrated safety and efficacy.

Based on results of the recently reported phase 3 CheckMate 274 trial, the FDA has granted priority review designation to nivolumab for the adjuvant treatment of high-risk muscle-invasive bladder cancer.

Accelerated approval for atezolizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for certain chemotherapy regimens was maintained by an FDA committee vote.

ONCOLOGY reviews key updates in the treatment of renal cell carcinoma to come out of the Genitourinary Cancers Symposium.

Based on results from the EV-301 and EV-201 trials, 2 separate applications for enfortumab vedotin as therapy for certain patients with previously treated metastatic urothelial carcinoma were accepted by the FDA and granted priority review.

Based on results of the phase 2 TROPHY-U-01 trial, the FDA has given accelerated approval to sacituzumab govitecan for previously treated, locally advanced or metastatic urothelial carcinoma.

Leonard G. Gomella, MD, FACS, detailed updated information regarding the standard of care and overall management of patients with non-muscle invasive bladder cancer at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.

Scott G. Hubosky, MD, of Jefferson University Hospitals, discussed methods of treating patients with upper tract urothelial carcinoma at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.

As part of an industry-wide assessment of indications based on accelerated approval, Roche in consultation with the FDA has decided to withdraw the indication for atezolizumab in patients with urothelial carcinoma following platinum-based chemotherapy.

Data published in The Lancet Oncology found that a hypofractionated radiation schedule of 55 Gy in 20 fractions is noninferior to a schedule of 64 Gy in 32 fractions for patients with this disease.

Continued approval for durvalumab in previously treated adult patients with locally advanced or metastatic bladder cancer was dependent upon results from the phase 3 DANUBE trial in the first-line metastatic bladder cancer setting, which did not meet its primary end points in 2020.

The biologics license application is for the locally administered fusion protein Vicineum for the treatment of high-risk, bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer.

In patients with cisplatin-ineligible, locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors, enfortumab vedotin induced the highest response rates seen with any regimen in this setting.

In non-muscle invasive bladder cancer carcinoma in-situ that is not responsive to BCG alone, the addition of N-803 leads to efficacy while maintaining safety.

Adjuvant therapy with nivolumab was superior to placebo for improving disease-free survival in patients with muscle-invasive urothelial carcinoma.

Recently reported data continue to support the use of enfortumab vedotin in patients with advanced urothelial carcinoma who had previously been treated with chemotherapy and immunotherapy.

Using the single-agent atezolizumab (Tecentriq) plus chemotherapy versus chemotherapy alone to treat patients in the front-line setting with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma (mUC) revealed additional clinical evidence.

Avelumab plus best supportive care as frontline maintenance therapy produced a favorable benefit-risk balance for Japanese patients with advanced urothelial cancer who did not progress on first-line chemotherapy.

High response rates with novel eganelisib plus PD-1 inhibition is reported in patients with metastatic urothelial carcinoma, especially those with low PD-L1 expression.

The procedure provided effective, long-term local control for patients with localized penile cancer, highlighting the need for a multidisciplinary approach to patient care.

The FDA  approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.

Results of this phase III trial could change the current standard of care for treating nonseminomatous or combined germ cell tumors of the testis.

The study found that patients who were randomized to receive avelumab and best supportive care lived significantly longer than those who only received best supportive care.

A new study used two patient-reported measures of sexual function following radical prostatectomy to assess sexual interest and satisfaction in men with prostate cancer.

Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results.

Researchers compared several glucocorticoid regimens, given in combination with abiraterone acetate, for metastatic castration-resistant prostate cancer.

In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.

In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.

An analysis of the ARAMIS trial looked at quality of life and other outcomes with darolutamide in men with nonmetastatic castration-resistant prostate cancer.

The PAIREDCAP trial looked at different biopsy approaches to see which has the highest cancer detection rate for prostate cancer.